Qoolabs, Inc

Antibody Discovery & Development

Qoolabs is the leading provider of rabbit monoclonal antibody services for research, diagnostic, and therapeutic development applications. The company's proprietary QMAb™ (Quick Monoclonal Antibody from Blood) platform rapidly generates novel monoclonal antibodies from rabbit peripheral blood mononuclear cells.

QMAb™ Process

The platform combines four major steps:

1. Rabbit immunization (8–12 weeks)
2. Cloning of variable domains from antibody-secreting cells in peripheral blood (4 weeks)
3. Validation by ELISA and functional assays (4 weeks)
4. Recombinant antibody expression and production (2 weeks)

Total timeline: approximately 3–4 months from initial immunization to antibody clones.

Key Advantages

• High-quality mAbs: Exceptional affinity and specificity through single-cell interrogation
• Natural pairing: Heavy and light chains are naturally paired, yielding highly stable antibodies with high production yield
• Animal welfare: Uses peripheral blood mononuclear cells; animals are retained for additional research and polyclonal antibody collection
• Adaptable screening: Supports epitope-specific screening, differential screening, and special binding assays
• Challenging targets: Successfully develops antibodies to small molecules, peptides, membrane proteins, GPCRs, and complex mixtures

Applications

Qoolabs has generated antibodies for:

• Single amino acid mutation differentiation
• Anti-idiotype antibodies
• Immunohistochemistry (IHC)
• Flow cytometry (FACS)
• Lateral flow immunoassays and ELISA
• Viral neutralization assays

Catalog Products

Hundreds of ready-made rabbit monoclonal antibodies are available, including anti-HCV core, anti-HBV core, anti-SARS-CoV-2 N and S proteins, anti-Guinea pig cytokines, anti-streptavidin, anti-FITC, anti-Group A Streptococcus, and anti-Monkeypox virus antibodies.